Skip to content

CTEV CTEV Additional Paid-In Capital

Additional Paid-In Capital at other companies

UnitedHealth Group logo
UnitedHealth GroupUNH
$556M
Evolent Health, Inc. logo
Evolent Health, Inc.EVH
$1.8B0.0%
Corvel logo
CorvelCRVL
$268.51M+7.2%
ROP
Roper Technologies, Inc.ROP
$3.33B+7.3%
Cognizant logo
CognizantCTSH
$17M-10.5%
Phreesia logo
PhreesiaPHR
$1.2B+6.2%

Other financials

Income statement

See full
Revenue$244.7M+5.8%
Gross profit$175.6M+2.8%
Operating income$6.6M-31.9%
Net income-$73.6M-3.1%
EPS (diluted)-$4.41-0.7%

Balance sheet

See full
Cash & equivalents$34.7M+2.4%
Total debt$4.7B+1.1%
Total equity-$241.1M-1,727%
Total assets$4.8B-4.8%

Cash flow

See full
Operating cash flow-$45.8M-52.3%
CapEx$46.8M+20.3%
Free cash flow-$92.5M-34.3%

Valuation

See full
Market cap$591.9M-10.0%
Enterprise value$5.22B
P/S0.6×

Profitability

See full
Gross margin73.2%-0.9pp
Operating margin-0.5%-0.3pp
Net margin-29.3%-12.7pp
FCF margin-10.6%

Returns & leverage

See full
Return on equity-198.7%-274pp
Debt / equity310.9×+307×
Current ratio1.3×+0.3×

Where this comes from

Reported directly by CTEV in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: CTEV’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CTEV's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CTEV's additional paid-in capital?
CTEV (CTEV) reported additional paid-in capital of $2.4B in Q1 2026.
How has CTEV's additional paid-in capital changed year-over-year?
CTEV's additional paid-in capital increased by 1.1% year-over-year, from $2.38B to $2.4B.
What is the long-term trend for CTEV's additional paid-in capital?
Over 5 years (2020 to 2025), CTEV's additional paid-in capital has grown at a -1.1% compound annual growth rate (CAGR), from $2.53B to $2.4B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.